Advanced search
Publication Cover
mAbs Volume 11, 2019 - Issue 5
Submit an article Journal homepage
3,109
Views
5
CrossRef citations to date
0
Altmetric
Meeting Report

Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6th antibody industrial symposium, June 25-26, 2018, Montpellier, France

Pierre MartineauIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, FranceView further author information
,
Hervé WatierEA7501 GICC, Université de Tours et CHRU de Tours, Tours, FranceView further author information
,
Andre PèlegrinIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, FranceCorrespondence[email protected] [email protected]
View further author information
&
Andrei TurtoiIRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier, FranceCorrespondence[email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0003-3813-6635View further author information
ORCID Icon
Pages 812-825 | Received 19 Apr 2019, Accepted 24 Apr 2019, Published online: 16 May 2019

References

  • Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. mAbs. 2015;7:9–14. doi:10.4161/19420862.2015.989042.
  • Kaplon H, Reichert JM. Antibodies to watch in 2018. mAbs. 2018;10:183–203. doi:10.1080/19420862.2018.1415671.
  • Küry P, Nath A, Créange A, Dolei A, Marche P, Gold J, Giovannoni G, Hartung H-P, Perron H. Human endogenous retroviruses in neurological diseases. Trends Mol Med. 2018;24:379–94. doi:10.1016/j.molmed.2018.02.007.
  • Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25–36. doi:10.1038/nrneurol.2016.187.
  • Segal NH, Naidoo J, Curigliano G, Patel S, Sahebjam S, Papadopoulos KP, Gordon MS, Wang D, Gómez Rueda A, Song X, et al. First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer. J Clin Oncol. 2018;36:3540–3540. doi:10.1200/JCO.2018.36.15_suppl.3540.
  • Cohen R, Fayette J, Posner M, Lefebvre G, Bauman J, Salas S, Even C, Seiwert T, Colevas D, Jimeno A, et al. Abstract CT158: phase II study of monalizumab, a first-in-class NKG2A monoclonal antibody, in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): preliminary assessment of safety and efficacy. Cancer Res. 2018;78:CT158–CT158.
  • Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK, Swerdlow H, Satija R, Smibert P. Simultaneous epitope and transcriptome measurement in single cells. Nat Methods. 2017;14:865–68. doi:10.1038/nmeth.4380.
  • Clark JE, Dudler T, Marber MS, Schwaeble W. Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction. Open Heart. 2018;5:e000652. doi:10.1136/openhrt-2017-000652.
  • Sijbrandi NJ, Merkul E, Muns JA, Waalboer DCJ, Adamzek K, Bolijn M, Montserrat V, Somsen GW, Haselberg R, Steverink PJGM, et al. A Novel Platinum(II)-based bifunctional ADC 89Zr-desferal and auristatin F-Conjugated trastuzumab. Cancer Res. 2017;77:257–67. doi:10.1158/0008-5472.CAN-16-1900.
  • Maurel D, Comps-Agrar L, Brock C, Rives M-L, Bourrier E, Ayoub MA, Bazin H, Tinel N, Durroux T, Prézeau L, et al. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization. Nat Methods. 2008;5:561–67. doi:10.1038/nmeth.1213.
  • Terral G, Champion T, Debaene F, Colas O, Bourguet M, Wagner-Rousset E, Corvaia N, Beck A, Cianferani S. Epitope characterization of anti-JAM-A antibodies using orthogonal mass spectrometry and surface plasmon resonance approaches. mAbs. 2017;9:1317–26. doi:10.1080/19420862.2017.1380762.
  • Fouquet G, Guidez S, Richez V, Stoppa A-M, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, et al. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget. 2018;9:23890–99. doi:10.18632/oncotarget.v9i35.
  • Beck A, Goetsch L, Dumontet C, Corvaïa N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37. doi:10.1038/nrd.2016.268.
  • Strickland LA, Ross J, Williams S, Ross S, Romero M, Spencer S, Erickson R, Sutcliffe J, Verbeke C, Polakis P, et al. Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma. J Pathol [Internet]. 2009; [cited 2009 Apr 3]. Available fromhttp://www.ncbi.nlm.nih.gov.gate2.inist.fr/pubmed/19334050.
  • Rivat C, Sar C, Mechaly I, Leyris J-P, Diouloufet L, Sonrier C, Philipson Y, Lucas O, Mallié S, Jouvenel A, et al. Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice. Nat Commun. 2018;9:1042. doi:10.1038/s41467-018-03496-2.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.